Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU

Cancer Immunology, Immunotherapy

Volumn 56, Issue 10, 2007, Pages 1605-1613

  Hou, Sheng ^a,b   Kou, Geng ^a,b   Fan, Xiaoqiang ^a   Wang, Hao ^a,b   Qian, Weizhu ^a,b   Zhang, Dapeng ^a   Li, Bohua ^a,b   Dai, Jianxin ^a   Zhao, Jian ^a   Ma, Jing ^a   Li, Jing ^a,b   Lin, Birong ^b   Wu, Mengchao ^a   Guo, Yajun ^a,b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Center for Cell Engineering and Antibody   (China)

Author keywords

5 Fu; Colon cancer; Flt3L; Hepatoma; Immunity

Indexed keywords

ADENOVIRUS VECTOR; ANTIINFECTIVE AGENT; FLUOROURACIL; FMS LIKE TYROSINE KINASE 3 LIGAND; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DISEASE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER TISSUE; CELL MATURATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOMEGALOVIRUS; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; LIVER CELL CARCINOMA; LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSFUSION; TUMOR IMMUNITY;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW; CARCINOMA, HEPATOCELLULAR; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CYTOMEGALOVIRUS; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; HEMATOPOIESIS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; PROMOTER REGIONS (GENETICS); SPLEEN;

EID: 34447644973     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0306-3     Document Type: Article

References (23)

1. Borges L, Miller RE, Jones J, Ariail K, Whitmore J, Fanslow W, Lynch DH. (1999) Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol 163(3):1289-1297
2. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, Guha C. (1999) Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 59(24):6028-6032
3. Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ. (2000) Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 164(7):3705-3712
4. Djazayeri K, Szilvassy Z, Peitl B, Nemeth J, Nagy L, Kiss A, Szabo B, Benko I (2005) Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment. Eur J Pharmacol 522(1-3):122-129
5. Drakes ML, Lu L, Subbotin VM, Thomson AW (1997) In vivo administration of flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J Immunol 159(9):4268-4278
6. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L (1999) Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5(4):405-411
7. Guo YJ, Che XY, Shen F, Xie TP, Ma J, Wang XN, Wu SG, Anthony DD, Wu MC. (1997) Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med 3(4):451-455
8. Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, Ma J, Sy MS (1994) Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263(5146):518-520
9. Gyobu H, Tsuji T, Suzuki Y, Ohkuri T, Chamoto K, Kuroki M, Miyoshi H, Kawarada Y, Katoh H, Takeshima T, Nishimura T (2004) Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor. Cancer Res 64(4):1490-1495
10. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J et al (1994) Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368(6472):643-648
11. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95(5):2509-2514
12. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR et al (1993) Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75(6):1157-1167
13. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3(6):625-631
14. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184(5):1953-1962
15. Mazzolini G, Qian C, Narvaiza I, Barajas M, Borras-Cuesta F, Xie X, Duarte M, Melero I, Prieto J (2000) Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum Gene Ther 11(1):113-125
16. McKenna HJ, de Vries P, Brasel K, Lyman SD, Williams DE. (1995) Effect of flt3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells. Blood 86(9):3413-3420
17. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. (1998) FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol 161(11):6164-6170
18. Sang H, Pisarev VM, Munger C, Robinson S, Chavez J, Hatcher L, Parajuli P, Guo Y, Talmadge JE (2003) Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity. Vaccine 21(21-22):3019-3029
19. Shaw SG, Maung AA, Steptoe RJ, Thomson AW, Vujanovic NL. (1998) Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol 161(6):2817-2824
20. Steptoe RJ, Fu F, Li W, Drakes ML, Lu L, Demetris AJ, Qian S, McKenna HJ, Thomson AW. (1997) Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. J Immunol 159(11):5483-5491
21. Wang H, Dai J, Hou S, Qian W, Li B, Ma J, Fan X, Zhao J, Yang S, Sang H, Yang Q, Wang R, Guo Y. (2005) Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy. Cancer Gene Ther 12(9):769-777
22. Wang A, Braun SE, Sonpavde G, Cornetta K. (2000) Antileukemic activity of Flt3 ligand in murine leukemia. Cancer Res 60(7):1895-1900
23. Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE. (2002) Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 8(4):343-348